The p53 Colorectal Cancer Trial

Summary

Single center, open labeled, phase 2 clinical trial, where patients with metastatic colorectal cancer are selected for treatment with dose dense Cyclophosphamide every second week based on TP53 mutation status; i.e. only patients with TP53 mutated tumors may be included in the treatment arm.

Timeline

Start

2017-05-09

Primary completion

2020-08-07

Completion

2020-08-07

Outcome

Outcome not reported

Stopped: “The study was discontinued after the first pre-planned interim analysis due to insufficient response rates.”

Drugs

Indications